Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. 

Blackstone Group

4BIO Capital

PPF Group

Woodford Investment Management

Arix Bioscience

Cormorant Asset Management

Google Ventures

Nextech Invest

Syncona Partners LLP

UCLB

Autolus Therapeutics

Adaptimmune Therapeutics is a biopharmaceutical company focused on the development of novel cancer immunotherapy products.

Adaptimmune Therapeutics

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company that develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1) for adult ALL, AUTO1/22 for pediatric ALL, AUTO4 for peripheral T-cell lymphoma, AUTO6NG for neuroblastoma, and AUTO8 for multiple myeloma. It also focuses on developing AUTO5 for peripheral T-cell lymphoma.

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics plc

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 8, 2024 12:20 PM	8e846933
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 8, 2024 12:20 PM	5849f0cc
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	2cb0c554
crunchbase profile	general	Nov 27, 2024 1:22 PM	baf00135
li profile	general	Feb 8, 2024 12:20 PM	d017dead
translate crunchbase fundingrounds	general
peers	general	Feb 8, 2024 12:20 PM	0c0d47aa
news basic	general	Feb 8, 2024 12:20 PM	b466d447
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AUTOLUS

Autolus Therapeutics plc

Last Close

2.84

22/11 21:00

Market Cap

609.42M

Beta: -

Volume Today

1.60M

Avg: -